TPM3 and metastatic neoplasm: Twenty-four patients were excluded; eight had previously been treated with a TRK inhibitor (all with larotrectinib, one had also received entrectinib), eight had a visit gap since advanced/metastatic diagnosis of >90 days, six had a diagnosis of advanced/metastatic disease made before 2011, and two had received an unlabeled drug during a clinical trial.